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Smart surface-enhanced Raman scattering
traceable drug delivery systems†
Lei Liu,a Yonghong Tang,b Sheng Dai,*a Freddy Kleitzc and Shi Zhang Qiao*a
A novel smart nanoparticle-based system has been developed for tracking intracellular drug delivery
through surface-enhanced Raman scattering (SERS). This new drug delivery system (DDS) shows targeted
cytotoxicity towards cancer cells via pH-cleavable covalent carboxylic hydrazone links and the SERS tracing
capability based on gold@silica nanocarriers. Doxorubicin, as a model anticancer drug, was employed to
compare SERS with conventional ﬂuorescence tracing approaches. It is evident that SERS demonstrates
higher sensitivity and resolution, revealing intracellular details, as the strengths of the original Raman signals
can be ampliﬁed by SERS. Importantly, non-destructive SERS will provide the designed DDS with great
autonomy and potential to study the dynamic procedures of non-ﬂuorescent drug delivery into living cells.
Introduction
Most of the small-molecule anticancer drugs have potent
chemotherapeutic characteristics, but their therapeutic
eﬃcacy is often limited by severe side eﬀects caused by sys-
temic toxicity and rapid resistance or aggregation issues
caused by poor solubility, low stability and unsuitable pharma-
cokinetic profiles as well as the lack of selectivity.1,2 For the
improvement of the practical and clinical performances of
drugs to combat human cancer, nanoparticle-based drug deliv-
ery systems (DDSs) have, over the recent years, drawn worldwide
attention in the field of anticancer research. For example,
impressive eﬀorts have been made to construct physical feature-
controlled,3,4 highly biocompatible5 and multifunctional6 DDSs.
Among those nanoparticles applied for drug delivery, silica
nanoparticles (SNs) possess the excellent properties of high
stability against chemical, mechanical and thermal changes, as
well as high biocompatibility and straightforward surface
functionalisation,7–9 thus they are considered as an ideal plat-
form for functional DDSs. Unlike physical adsorption and
diﬀusion, which may lead to premature, burst drug release and
ultimately severe side eﬀects, smart covalent linkages between
the drug and carrier, especially carboxylic hydrazone links,10–12
could bring eﬀective impacts on sustainable drug release and
reduce side eﬀects, making the development of such smart
DDSs a high priority.
When it comes to tracking the intracellular performance of
DDSs, the conventional widely implemented approach is fluo-
rescence evaluation. However, it has certain inevitable limit-
ations. In general, DDSs require artificial labelling, which
might change physicochemical properties, uptake pathways
and pharmacological eﬀects of the loaded drugs. Moreover,
photo-bleaching fluorophores and the fluorescent background
interruptions from cells tend to limit long-term tracing.13 As
the characteristic peak in the fluorescence spectra is very
broad, it raises the diﬃculty of distinguishing overlapping
spectra from multi-fluorescence labelled tracing systems.14
Conversely, surface-enhanced Raman scattering (SERS) has
been introduced into life science research,14–16 where these
fluorescence barriers could be mitigated and crossed. The
results of SERS tracing demonstrate high sensitivity and
resolution features, as the strength of the original Raman peak
can be theoretically enhanced to 8–11 orders of magnitude by
SERS.17–19 Enhancement of fingerprint Raman signals (10–100
times narrower than fluorescence14) can materialise the navi-
gation pathway of a single molecule from samples, cells, or
even intracellular compartments. However, only limited work
has been performed in the area of SERS-tracking drug delivery.
For instance, single metal nanoparticles with a silica coating
of size larger than 100 nm were reported,20 as this size of
noble metal particles is acceptable for SERS tracing. However,
clusters of small (5–10 nm) metal nanoparticles can also form
hot spots in the junctions between them to enhance Raman
signals,16 which could make them suitable to replace larger
single nanoparticles as the most eﬀective SERS traceable
agents. However, to date, DDSs based on small metal nano-
particle-induced SERS have remained largely unexplored.
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Herein, a smart SERS traceable drug delivery system (DDS)
has been constructed, in which the drug-carrier linkages are
pH-cleavable. Silica nanoparticles (SNs) are viewed as the
framework, and small exposed gold particles with SERS repor-
ters are settled on SNs. Owing to the covalent pH-cleavable
drug-carrier links, the chosen anticancer drug (DOX) will
remain conjugated into the DDS to avoid premature and
uncontrolled drug leakage in healthy cell regions. As shown in
Scheme 1, when delivered to cancer cells, the chemical links of
the DDS will be cleaved by the more acidic surroundings of the
cancer cells, and DOX will be dissociated and released into the
cells to perform its pharmacological purpose. Therefore, this
smart DDS design will oﬀer targeted cytotoxicity while being
eﬃciently tracked by SERS.
Experimental
Chemicals
Fetal bovine serum (FBS), Dulbecco’s modified eagle medium
(DMEM), pH = 7.4 phosphate buﬀered saline (PBS), antibiotic-
antimycotic (Anti-anti, 100×), 0.25% (w/v) trypsin–0.03% (w/v)
ethylenediaminetetraacetic acid (EDTA) solution, 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
and LIVE/DEAD® viability/cytotoxicity kit (calcein-AM/ethi-
dium homodimer-1) were purchased from Life Technologies
Australia Pty Ltd. Doxorubicin hydrochloride (DOX), which is
selected as a model drug for cancer therapy, was purchased
from Beijing Huafeng United Technology Co Ltd. Gold(III)
chloride trihydrate (HAuCl4·3H2O) and aqueous ammonia
(NH4OH, 25%) were purchased from Chem-Supply Australia
Pty Ltd. Sodium borohydride (NaBH4), N-hydroxysuccinimide
(NHS), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide
hydrochloride (EDC), 4-mercaptobenzoic acid (4-MBA), tetra-
ethyl orthosilicate (TEOS, ≥98%), (3-aminopropyl)triethoxy-
silane (APTES, ≥98%), sodium citrate (Na3Ct), trifluoroacetic
acid (TFA), N,N-dimethylformamide (DMF), tert-butyl carbazate
(Boc-NHNH2), succinic anhydride, dimethyl sulfoxide (DMSO)
and other chemicals were purchased from Sigma Aldrich. All
materials were of analytical grade and used as received
without further purification. Millipore water was obtained
from a three-stage Millipore Mill-Q plus 185 purified cation
system (Academic) with a resistivity higher than 18.2 MΩ cm.
Characterisation
Scanning electron microscopy (SEM) observations were carried
out on an FEI Quanta 450 FEG environmental emission scan-
ning electron microscope operated at 10 kV. A 5 nm platinum
layer coating by ion sputtering was required for each specimen
before SEM observation. For obtaining transmission electron
microscopy (TEM) images, an FEI Tecnai G2 Spirit trans-
mission electron microscope at an acceleration voltage of
120 kV was employed. Fourier transform infrared (FTIR)
spectra were recorded at room temperature on a Thermo Scien-
tific NICOLET 6700 FTIR spectrometer. The hydrodynamic
sizes and zeta-potentials of diﬀerent products dispersed in de-
ionized water were determined at room temperature by using a
Malvern Zeta-sizer Nano ZS (Malvern Inst. Ltd, UK) equipment.
The concentration of particles in water was kept at 0.1 ±
0.05 mg mL−1 for particle size analysis, while the zeta potential
results were calculated based on the statistical analysis of 10
parallel runs. The pH values were measured by using a pH
meter (EL20, METTLER TOLEDO). UV-Vis absorption spectra
were recorded on a UV-2600 spectrophotometer (Shimadzu Cor-
poration). X-ray diﬀraction (XRD) patterns were obtained on a
powder X-ray diﬀractometer at 40 kV and 15 mA using Co-Kα
radiation (Miniflex, Rigaku). In addition, an Axis Ultra (Kratos
Analytical, UK) XPS spectrometer equipped with an Al Kα source
(1486.6 eV) was used for X-ray photoelectron spectrum (XPS) col-
lection. Fluorescence excitation and emission images were
obtained on a ZEISS Axio Vert. A1 inverted microscope equipped
with 488 nm and 530 nm lasers. A HORIBA Lab RAM HR Evol-
ution equipped with a 785 nm laser was employed for obtaining
Raman spectra and SERS mapping images.
Synthetic procedures of SN-NH2
The SN-NH2 were fabricated by a modified direct Stöber
approach.21 In a typical synthesis run, TEOS (2.3 mL) was
quickly added to a mixed solution of 25% aqueous ammonia
(3.0 mL), deionized water (1.0 mL), and ethanol (60 mL). The
magnetic stirring rate is ca. 800–1000 rpm. The mixture was
stirred at 40 °C for 4 h, and then 0.1 mL APTES was added into
the system. After 800–1000 rpm stirring for another 2 h at
40 °C and washing with ethanol, the aminated silica nano-
spheres, labelled as SN-NH2, were obtained.
Synthetic procedures of Au–SN-NH2
The gold nanoparticles were prepared by the NaBH4 and Na3Ct
reduction method.22,23 1.0% HAuCl4·3H2O (0.1 mL) and de-
Scheme 1 Schematic diagram representing the synthesis of doxo-
rubicin-conjugated SERS nanocomposites and the pathway of intra-
cellular drug release.
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ionized water (9 mL) were stirred for 1 min with 800–1000 rpm
stirring rate at room temperature, and then 38.8 mM Na3Ct
(0.2 mL) was added into the system. After adding 0.075%
NaBH4 (0.1 mL), gold nanoparticles of ca. 5–10 nm were syn-
thesised. Subsequently, these gold nanoparticles were attached
to the SN-NH2 with a gold nanoparticle-to-SN molar ratio of 4,
under 30 min sonication in deionized water. The resulting Au–
SN-NH2 nanoparticles were centrifuged and then washed with
ethanol, and the final precipitates were dried in an oven at
60 °C for 24 h.
Synthetic procedures of 4-MBA–Au–SN-NHNH2
As illustrated in Scheme 1, 100 mg Au–SN-NH2 particles were
dispersed in DMF (12 mL) by ultrasonic treatment. 900 mg
succinic anhydride was dissolved in DMF and then added into
the prepared Au–SN-NH2 suspension. After stirring for 6 h at
room temperature, the products were centrifuged, washed with
ethanol and water and dried to obtain Au–SN-COOH powder.
Then, Au–SN-COOH particles were added in DMF (20 mL), and
stirred with 54 mg EDC and 32 mg NHS for 1 h at room tem-
perature, before 37 mg Boc-NHNH2 were finally added into the
system. The mixture was further stirred at room temperature
for another 24 h. The products were centrifuged, washed with
ethanol and water and dried to yield Au–SN-NHNH-Boc. To
remove the protective Boc group, Au–SN-NHNH-Boc particles
were dispersed in a mixture of DMF (10 mL) and TFA (5 mL).
The system was stirred at room temperature for 24 h, before
the final products Au–SN-NHNH2 were centrifuged, washed
with ethanol and dried in an oven at 60 °C. 1 mM 4-MBA was
added to the Au–SN-NHNH2 aqueous suspensions with a
molar ratio of 1 : 100. After stirring for 24 h at room tempera-
ture, the SERS tag 4-MBA was integrated onto the gold nano-
particles. The 4-MBA–Au–SN-NHNH2 nanocarriers were
centrifuged and then washed several times with ethanol to
remove any unreacted 4-MBA, and the final precipitates were
dried in an oven at 60 °C for 24 h.
DOX conjugation and in vitro release
Regarding doxorubicin conjugation (Scheme 1), 1.0 mg of
dried 4-MBA–Au–SN-NHNH2 nanocarriers was added into ca.
0.5 mg mL−1 DOX/PBS solution, and stirred at 1000 rpm at
room temperature for 24 h in a dark environment. After
washing with ethanol 3 times, the final 4-MBA–Au–SN–hydra-
zone–DOX products were collected by centrifugation, washed
with standard pH 7.4 PBS and dried in an oven at 60 °C for
24 h. The supernatant of the initial DOX/PBS solution and all
the washing supernatants were collected for the evaluation of
the DOX conjugation eﬃciency. The corresponding DOX doses
were estimated by using 480 nm UV-vis adsorption values and
a standard DOX calibration curve.
The release profiles of DOX from 4-MBA–Au–SN–hydra-
zone–DOX were evaluated independently in three PBS media
with diﬀerent pH values 5.0, 6.0 and 7.4. The pH value of each
system was adjusted using acetate buﬀer and PBS, and
measured by using a pH meter. For each release investigation,
5 mg DOX-conjugated particles were added into the buﬀer
solution (5 mL), and continuously stirred with a rate of
100 rpm at 37 °C under dark conditions. 1 mL of release
medium was removed at selected time intervals. The super-
natant was centrifuged for drug release analysis, and the
residual parts together with an identical amount of fresh
buﬀer solution were put back into the system. The released
amounts of DOX were analysed by using 480 nm UV-vis
adsorption values and a standard DOX calibration curve.
Cytotoxicity studies
The cell viability results obtained by MTT assays against
human cervical cancer HeLa cells and human embryonic
kidney HEK 293 cells were used to investigate the cytotoxicities
of the fabricated nanocarriers 4-MBA–Au–SN-NHNH2 before
and after DOX conjugation. Both HeLa and HEK293 cells were
incubated in cell culture medium (DMEM, 10% FBS and 1×
Anti-anti) at 37 °C in a 5% CO2 humid environment. For MTT
assays, cells were seeded into a 96-well plate at a density of 5 ×
104 cells per mL, and incubated for 24 h in cell culture
medium (0.1 mL). Subsequently, an identical volume of cell
culture medium (0.1 mL) containing diﬀerent particles (nano-
carriers, DOX-conjugated products and free DOX) was replaced
by the previous medium and further incubated for 24 h. Then,
0.5 mg mL−1 MTT (0.01 mL) was added to each well, and after
incubation for 4 h, DMSO (0.15 mL) was used to replace the
medium and dissolve formazan crystals. The MTT assays were
conducted in quadruplicate for each sample, and the final
absorbance of formazan crystals was measured by using an
ELx808 Absorbance Microplate Reader (Biotek, USA) at a wave-
length of 595 nm.
The cytotoxicity results of 4-MBA–Au–SN–hydrazone–DOX
were further confirmed by using fluorescence LIVE/DEAD® via-
bility/cytotoxicity studies. HEK293 and HeLa cells were added
into a 24-well plate at 5 × 104 cells per mL seeding density, and
incubated in cell culture medium (1 mL) for 24 h. Later,
0.2 mg mL−1 DOX-conjugated products in cell culture medium
(1 mL) were replaced and incubated for another 24 h. After
removal of the medium and PBS washing, the cells were
harvested by using EDTA and resuspended in PBS solution.
0.4 mL LIVE/DEAD® viability/cytotoxicity kit (2 µM calcein-AM
and 4 µM ethidium homodimer-1) was added in a dark
environment, and then incubated for 30 min. The cells were
gently washed with PBS to remove excessive dyes. The final
cytotoxicity results were checked by using images obtained
with a fluorescence microscope.
SERS tracking of 4-MBA–Au–SN–hydrazone–DOX
HeLa cells were seeded at a concentration of 2 × 105 cells per
mL with 2 mL cell culture medium per well into a 6-well plate
with 22 mm cover-glass slides inside, and incubated for 24 h
at 37 °C under 5% CO2. The fresh medium (2 mL) containing
0.4 mg DOX-conjugated products was replaced and incubated
for another 4 h. Subsequently, the glass substrate with cells
and DOX conjugated products was collected after three times
of gentle washing with PBS. The Raman study was conducted
with a 785 nm laser and 100× objectives. The area is 30 ×
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30 μm with a resolution of 961 data points for mapping. The
acquisition time for each data point is 1 s.
Flow cytometry analysis of 4-MBA–Au–SN–hydrazone–DOX
In terms of flow cytometry analysis, 0.2 mg mL−1 DDSs were
dispersed in cell culture medium (DMEM with 10% FBS and
1% PS). HeLa cells were added into a 24-well plate at 2 × 104
cells per mL seeding density, and incubated in 1 mL cell
culture medium for 24 h at 37 °C under 5% CO2. Fresh media
(1 mL) containing 0.2 mg mL−1 4-MBA–Au–SN–hydrazone–
DOX was incubated for diﬀerent time periods. The cells were
harvested by the digestion of EDTA solution, and gently
washed with PBS twice. With a 200–600 cells per second flow
rate, ca. 1 × 104 cells were analysed by using a FACS Calibur
flow cytometer (Becton Dickinson). The testing result of
healthy HeLa cells was selected as a negative control, and the
red fluorescence intensities of DOX were directly measured by
cytometry. The data were analysed using Cell Quest 3.3 soft-
ware, while one-color flow cytometry was used to evaluate cel-
lular uptake.
Results and discussion
Characterization of the smart drug delivery system
The 4-MBA–Au–SN–hydrazone–DOX smart DDS was prepared
following the procedure illustrated in Scheme 1. The amino-
functionalized silica nanoparticles (SN-NH2) were synthesized
in one pot by a modified Stöber method.21 The scanning elec-
tron microscopy image (SEM, Fig. 1a) and transmission elec-
tron microscopy image (TEM, Fig. 1b) demonstrate that SNs
are uniform nanospheres with an average particle diameter of
ca. 80–100 nm. The size results are further verified from
dynamic light scattering (DLS) measurements (Table S1† and
Fig. 2a), where the average hydrodynamic diameter of SN-NH2
is 91 nm with an average zeta potential of +18.3 mV. In the
FTIR spectra (Fig. S1†) of SN-NH2, the typical silica Si–O–Si
asymmetric stretching, Si–OH and Si–O symmetric stretching
vibrations can be observed at around 1066, 945 and 795 cm−1,
respectively.24 The –OH stretching vibration at approximately
1635 cm−1 may be the deformation band of physically
absorbed H2O. The 3357 cm
−1 peak is the signature of N–H
stretching vibrations, and N–H bending bands appear around
1500 cm−1. The existence of amino groups is crucial for
further anchoring of gold nanoparticles.
Gold nanoparticles (Au NPs) were synthesised by sodium
borohydride reduction and sodium citrate stabilization.22,24
Sphere-like Au NPs with an average 5–10 nm diameter can be
observed in the high resolution TEM images (Fig. 1c). The
hydrodynamic size of Au NPs measured by DLS (Table S1† and
Fig. 2a) is around 12 nm with a negative average zeta potential
of −33.1 mV, which is in line with the TEM size results. As dis-
played in the enlarged image (inset of Fig. 1c), the average dis-
tance of the lattice fringes is approximately 0.23 nm, which is
evidence of the presence of the (111) crystallographic
planes.24,25 As shown in Fig. S2a,† the surface plasmon reson-
ance (SPR) of the synthesised Au NPs, collected by UV-vis
measurements, can be clearly visible as a peak at 520 nm in
the UV-vis spectra. According to the reference experimental
data,23,26 this SPR peak fits the behaviour of spherical Au NPs
with the particle size range of 5–10 nm. In addition to the
theoretical calculation, the measured ratio of the absorbance
at the SPR peak to the absorbance at 450 nm is 1.20, and
according to the size in dependence of the particle diameter
data of spherical Au NPs,23 the particle diameter can be esti-
mated as 4–5 nm.
Au–SN-NH2 was formed by attachment of Au NPs on
SN-NH2 based on selective bonding between gold atoms and
the amine groups.27 From the DLS data (Table S1† and
Fig. 2a), the hydrodynamic diameter of Au–SN-NH2 is around
103 nm with an average zeta potential of +9.4 mV. The
decrease of zeta potential from SN-NH2 to Au–SN-NH2 may be
attributed to the presence of Au NPs linked to SN-NH2. Fur-
thermore, in Fig. S2a,† the SPR peak shifts from 520 nm to
535 nm, which might be due to the Au NP aggregation on the
silica particle surfaces. According to the wide-angle XRD
pattern (Fig. 2b) and standard pattern JCPDS card no. 04-0784,
the first broad diﬀraction pattern from the 2θ range 10 to
30° can be assigned to the amorphous silica component,
while the peaks at 2θ = 38.18°, 44.39°, 64.58° and 77.55°
correspond to the (111), (200), (220) and (311) planes of Au
NPs, respectively. The estimated average size of Au NPs cal-
culated using the Scherrer formula is about 5.5 nm, in
accordance with the full width at half maximum of the
intense (111) reflection of Au NPs. Furthermore, the FTIR
spectroscopy result (Fig. S1†) of Au–SN-NH2 is almost identi-
cal to SN-NH2, with signals at 1066, 945 and 795 cm
−1 con-
firming the presence of silica, while 3357 and 1500 cm−1
are evidence of the amino groups.
Fig. 1 Electron microscopy images. (a) SEM, (b) TEM images of
SN-NH2, (c) gold nanoparticles, and (d) Au–SN-NHNH2.
Paper Nanoscale




















































































Towards surface modification, two intermediate products,
Au–SN-COOH and Au–SN-NHNH-Boc, were synthesised. From
the DLS data (Table S1† and Fig. 2a), the hydrodynamic size of
Au–SN-COOH is about 115 nm with an average zeta potential
of −24.6 mV, while Au–SNsNHNH-Boc with a hydrodynamic
size of ca. 174 nm has an average zeta potential of +2.3 mV.
The negative–positive change of the zeta potentials could be
attributed to the conversion of surface groups from –COOH to
–NHNH-Boc. From the FTIR spectra (Fig. S1†), the peak at
1720 cm−1 is attributed to the symmetric stretching of –CvO,
which confirms the presence of carboxyl groups, while the
1657 cm−1 peak indicates the existence of –NH–CvO stretch-
ing vibrations.
After removing Boc groups using TFA,10 Au–SN-NHNH2 was
obtained. From the TEM image (Fig. 1d), the average particle
size is about 150–170 nm, combined with the ∼5–10 nm dark
spots recognized as Au NPs. By further characterization by DLS
(Table S1† and Fig. 2a), the hydrodynamic size of Au–
SN-NHNH2 is about 167 nm with an average zeta potential of
+15.4 mV. This size of nanocarriers is believed to be superior
for drug delivery applications not only for favouring the
enhanced permeability and retention eﬀects (EPR), but also
for limiting non-targeted cellular uptake and undesired cyto-
toxicity.28 The zeta potential increase from Au–SN-NHNH-Boc
to Au–SN-NHNH2 is attributed to the surface hydrazine groups
on Au–SN-NHNH2. The presence of hydrazine groups was also
confirmed by FTIR. The 3357 cm−1 N–H stretching and
1500 cm−1 N–H bending vibration peaks can be clearly identi-
fied in Fig. S1.†
4-MBA–Au–SN–hydrazone–DOX DDSs were created by
attaching 4-MBA as SERS tags,29,30 and DOX conjugation was
realized via a pH-cleavable carboxylic hydrazone linkage.10,31
In the FTIR spectra (Fig. S1†), the peak at 1734 cm−1 is
attributed to the –CvO symmetric stretching vibrations from
4-MBA. The signal at 1657 cm−1 represents the hydrazone
bonds, which arise from the reaction between hydrazine and
the carbonyl groups from DOX. Characteristic peaks at 1540,
1467 and 1412 cm−1 belong to the skeleton vibrations of the
ring of DOX,32 which proves the presence of DOX on the DDS
particles. The 2850 and 2917 cm−1 bands are attributed to C–H
vibrations.
The DOX conjugation was also verified by testing the fluo-
rescence of the well-washed DDS composites. From Fig. S2b,†
the 503 nm excitation and 557 nm emission peaks are evi-
dence of DOX linked to DDSs. Moreover, the X-ray photo-
electron spectroscopy results shown in Fig. 2c illustrate that
Fig. 2 (a) Zeta potentials of diﬀerent products at diﬀerent synthesis stages, (b) XRD patterns of SN-NH2 and Au–SN-NH2, (c) XPS spectra of DOX-
conjugated composites, and (d) the enlarged C 1s region.
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DDSs contain C, O, N and Si elements. However, the presence
of S from 4-MBA and Au element could not be detected plausi-
bly because of their too low surface contents. The enlarged C
1s region (Fig. 2d) demonstrates the presence of C–Si, C–C,
C–N, CvN, and CvO groups. These high resolution XPS
results confirm the occurrence of hydrazone bonds, which is
also proof of the DOX–hydrazone conjugations.
SERS eﬀective enhancement factor
The Raman spectra of bulk 4-MBA and 4-MBA–Au–SN-NHNH2
(Fig. 3) are compared to estimate the SERS eﬀective enhance-
ment factor (EEF).
For 4-MBA, the Raman peaks at 1099 cm−1 and 1595 cm−1
are attributed to ν8a and ν12 aromatic ring vibrations of
4-MBA.29 However, for 4-MBA–Au–SN-NHNH2, these two peaks
shift to 1078 cm−1 and 1580 cm−1, respectively. The occurrence
of such blue shifts confirms the interaction between 4-MBA
and Au NPs. The EEF can be estimated based on the calcu-




where ISERS and Ibulk are the intensities of SERS and bulk
spectra at the 1078 cm−1 band, and
Nbulk
NSERS
is the molar ratio
Fig. 3 Raman spectra of bulk 4-MBA and the SERS spectra of 4-MBA–
Au–SN-NHNH2.
Fig. 4 Cytotoxicity data of (a) SERS traceable nanocarriers, (b) DDSs and free DOX, and LIVE/DEAD® analysis of 24 h DDS incubation of (c) HEK293,
and (d) HeLa cells.
Paper Nanoscale




















































































between the bulk and SERS sample.29,33 Thus, the EEF of
4-MBA–Au–SN-NHNH2 is approximately 1.7 × 10
5.
Biocompatibility and targeted cytotoxicity of DDSs
The biocompatibility of the nanocarriers (4-MBA–Au–
SN-NHNH2) and the cytotoxicity of the DDS, and free DOX as a
reference, were determined and compared for the HeLa
(cancer) and HEK293 (healthy) cell lines. As shown in Fig. 4a,
the nanocarriers demonstrate great biocompatibility in both
cell lines. After 24 h of incubation at 37 °C under 5% CO2, cell
viabilities remained above 85%, for particle concentrations
below 200 µg ml−1.
For the DDS particles and free DOX, the results, shown in
Fig. 4b, reveal that cell viabilities are decreasing with the
increasing DOX equivalent concentration in both cell lines.
For free DOX, no distinct diﬀerences of cytotoxicity are
observed between the cell lines. However, for DDSs, the toler-
ability of HEK 293 cells is much better than that of HeLa cells
at high particle dosage. At 6.4 µg ml−1 of DOX equivalent con-
centration, the cell viability of HEK 293 is around 70%, which
is higher than the 30% in HeLa. This diﬀerence could be
attributed to the acidic-cleavage of the carboxylic hydrazone
bond existing between DOX and nanocarriers, which acceler-
ated the release of DOX from the nanocarriers in the cancer
cells. The diﬀerence in DDS cytotoxicities between cancer and
healthy cells evidences the feasibility of a pH-smart DDS. Fur-
thermore, the SERS tracing agents seem to exert little influence
on cellular selections. In addition, DDS cytotoxicities in both
HEK 293 and HeLa cell lines were investigated by LIVE/DEAD®
viability/cytotoxicity measurements. For this, 6.4 µg ml−1 DOX
equivalent concentration of DDS particles was incubated for
24 h in both the cell lines. Living cells were stained fluorescent
green with Calcein AM, while the dead cells were stained red
with ethidium homodimer-1. Fig. 4c and d show the merged
optical-fluorescence images of the HEK293 and HeLa cells. For
HEK293, the amount of fluorescent green live cells is more
than red ones with an estimated cell viability of 70%. While
for the HeLa cells, the amount of green living cells is lower
than that of the red dead cells, where the cell viability might
be estimated to be about 25%.
Cellular uptake using SERS tracing
The cellular uptake performances of the DDS in the HeLa cell
lines were analysed by SERS mapping and compared with the
fluorescence method. The DDS-treated cells were placed on a
microscopy glass substrate and directly observed by Raman
microscopy.
Fig. 5a shows the bright field image of the HeLa cells with a
30 × 30 µm mapping area (red square marked). This area
demonstrates a single-cell, and its enlarged image with 2
Fig. 5 (a) Optical image of HeLa cells with a red rectangle mapping area, optical images of the enlarged mapping area from the upper inset of (a)
ﬂuorescence, and the lower inset of (a) Raman microscopy with two selected positions 1 and 2, (b) Raman spectra of selected positions, (c) SERS
mapping image, (d) ﬂuorescence image, (e) merged optical-ﬂuorescence-SERS images, and (h) ﬂow cytometry results with diﬀerent DOX incubation
times.
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selected positions is shown in the lower inset of Fig. 5a. These
testing positions 1 and 2 are selected to represent the signal
obtained from the substrate and that from the cell, respect-
ively. Their corresponding SERS spectra are depicted in
Fig. 5b. Although there are background fluorescence interrup-
tions of the glass substrate around 400 and 1400 cm−1, the
narrow 1078 and 1580 cm−1 SERS peaks are readily distin-
guished. Thus, the SERS approach oﬀers a certain competitive
advantage over the fluorescence method, such as a finger-print
narrow band, high sensitivity and easily distinguished signals.
Fig. 5c shows the tracing image by SERS mapping, in which
the intensities of the 1078 cm−1 band are demonstrated by the
brightness of green cursors. The possibility of obtaining an
SERS tracing image of DDS intracellular performances vali-
dates the feasibility of the SERS tracing method. The fluo-
rescence tracing image of DOX (Fig. 5d) was obtained from the
same sample used in SERS mapping. Also, the DOX fluo-
rescence tracing was further checked by in vitro flow cytometry
analysis. DOX fluorescence is tracked from diﬀerent incu-
bation time points from 2 to 24 h. As demonstrated in Fig. 5f,
the DOX fluorescence intensity is proportional to the incu-
bation time, which is indicating the cellular uptake of DOX
molecules.34 To compare the SERS and fluorescence tracing
results, the fluorescence image was captured at the same posi-
tion of the same sample tested, and the enlarged optical
image obtained from fluorescence microscopy is shown in the
upper inset of Fig. 5a. This single-cell image is identical to the
optical image obtained from Raman microscopy shown in the
lower inset of Fig. 5a. The merged image in Fig. 5e demon-
strates the overlapping area of the optical, SERS and fluo-
rescence images. As the fluorescence tracing result agrees well
with the SERS one, eﬃcient SERS tracing is further confirmed.
Interestingly, the single-cell SERS tracing image exhibits high
resolution and reveals more intracellular details than the red
fluorescence one. The black area in the SERS image might
demonstrate the position of the cell nucleus, where the DDS
particles could not be delivered into.
Conclusions
A new smart DDS was designed through SERS-traceable nano-
carriers bearing a carboxylic hydrazone-conjugated DOX anti-
cancer agent. The SN platform contributes to the aggregation
of small exposed gold nanoparticles on their surfaces, which
benefits SERS tracing. The smart DDS is almost biocompatible
in healthy cells, while exhibits targeted cytotoxicities in cancer
cells. By choosing DOX as an anticancer model drug, intra-
cellular uptake of DDS particles could be traced by comparing
the SERS and fluorescence approaches. As SERS signals have
higher sensitivities than the fluorescence ones, it could eﬀec-
tively replace the fluorescence method in tracing. With further
consideration of the non-destructive features of SERS
methods, these designed DDSs might be implemented to
evaluate other general drugs without fluorescence analysis.
This point is also valid for general drugs without inhibiting
cell functions. In that case, we envision that these structured
nanocarriers might have the capability to unveil dynamic pro-
cesses of drug delivery in living cells.
Acknowledgements
This work was financially supported by the Australian
Research Council (ARC) Discovery Projects (DP140104062 and
DP130104459). Lei Liu acknowledges a scholarship from the
University of Adelaide. Freddy Kleitz acknowledges financial
support from the Natural Sciences and Engineering Research
Council of Canada (NSERC).
Notes and references
1 X. Zhang, F. Li, S. Guo, X. Chen, X. Wang, J. Li and Y. Gan,
Biomaterials, 2014, 35, 3650–3665.
2 F. Qiu, D. Wang, Q. Zhu, L. Zhu, G. Tong, Y. Lu, D. Yan and
X. Zhu, Biomacromolecules, 2014, 15, 1355–1364.
3 K. C. W. Wu and Y. Yamauchi, J. Mater. Chem., 2012, 22,
1251–1256.
4 V. Malgras, Q. Ji, Y. Kamachi, T. Mori, F.-K. Shieh,
K. C. W. Wu, K. Ariga and Y. Yamauchi, Bull. Chem. Soc.
Jpn., 2015, 88, 1171–1200.
5 H.-Y. Lian, M. Hu, C.-H. Liu, Y. Yamauchi and K. C. W. Wu,
Chem. Commun., 2012, 48, 5151–5153.
6 C. Argyo, V. Weiss, C. Bräuchle and T. Bein, Chem. Mater.,
2014, 26, 435–451.
7 X. Du, L. Xiong, S. Dai, F. Kleitz and S. Z. Qiao, Adv. Funct.
Mater., 2014, 24, 7627–7637.
8 Z. Teng, X. Su, Y. Zheng, J. Sun, G. Chen, C. Tian, J. Wang,
H. Li, Y. Zhao and G. Lu, Chem. Mater., 2013, 25, 98–105.
9 X. Fang, X. Zhao, W. Fang, C. Chen and N. Zheng, Nano-
scale, 2013, 5, 2205–2218.
10 J. Fan, G. Fang, X. Wang, F. Zeng, Y. Xiang and S. Wu,
Nanotechnology, 2011, 22, 455102.
11 Y. Zhang, C. Xiao, M. Li, J. Chen, J. Ding, C. He, X. Zhuang
and X. Chen, Macromol. Biosci., 2013, 13, 584–594.
12 C. Liu, F. Liu, L. Feng, M. Li, J. Zhang and N. Zhang, Bio-
materials, 2013, 34, 2547–2564.
13 A. Samanta, K. K. Maiti, K.-S. Soh, X. Liao, M. Vendrell,
U. S. Dinish, S.-W. Yun, R. Bhuvaneswari, H. Kim,
S. Rautela, J. Chung, M. Olivo and Y.-T. Chang, Angew.
Chem., Int. Ed., 2011, 50, 6089–6092.
14 M. Vendrell, K. K. Maiti, K. Dhaliwal and Y.-T. Chang,
Trends Biotechnol., 2013, 31, 249–257.
15 S. Zeng, D. Baillargeat, H.-P. Ho and K.-T. Yong, Chem. Soc.
Rev., 2014, 43, 3426–3452.
16 S. Schlücker, Angew. Chem., Int. Ed., 2014, 53, 4756–4795.
17 X. M. Qian and S. M. Nie, Chem. Soc. Rev., 2008, 37, 912–
920.
18 M. Fan, G. F. S. Andrade and A. G. Brolo, Anal. Chim. Acta,
2011, 693, 7–25.
Paper Nanoscale




















































































19 X. Gong, Y. Bao, C. Qiu and C. Jiang, Chem. Commun.,
2012, 48, 7003–7018.
20 S. Zong, Z. Wang, H. Chen, J. Yang and Y. Cui, Anal. Chem.,
2013, 85, 2223–2230.
21 Y. Takeda, Y. Komori and H. Yoshitake, Colloids Surf., A,
2013, 422, 68–74.
22 C. J. Johnson, E. Dujardin, S. A. Davis, C. J. Murphy and
S. Mann, J. Mater. Chem., 2002, 12, 1765–1770.
23 W. Haiss, N. T. K. Thanh, J. Aveyard and D. G. Fernig, Anal.
Chem., 2007, 79, 4215–4221.
24 X. Du and J. He, Nanoscale, 2012, 4, 852–859.
25 X. Li, H. Liu, J. Yang, S. Z. Qiao and X. W. Du, RSC Adv.,
2014, 4, 1185–1188.
26 G. A. López-Muñoz, J. A. Pescador-Rojas, J. Ortega-Lopez,
J. S. Salazar and J. A. Balderas-López, Nanoscale Res. Lett.,
2012, 7, 1–6.
27 S. Y. Quek, L. Venkataraman, H. J. Choi, S. G. Louie, M. S.
Hybertsen and J. B. Neaton, Nano Lett., 2007, 7, 3477–3482.
28 K. E. Schmalenberg, L. Frauchiger, L. Nikkhouy-Albers and
K. E. Uhrich, Biomacromolecules, 2001, 2, 851–855.
29 L. Wei, B. Jin and S. Dai, J. Phys. Chem. C, 2012, 116,
17174–17181.
30 A. Michota and J. Bukowska, J. Raman Spectrosc., 2003, 34,
21–25.
31 D. Li, J. Tang, C. Wei, J. Guo, S. Wang, D. Chaudhary and
C. Wang, Small, 2012, 8, 2690–2697.
32 A. Popat, J. Liu, Q. Hu, M. Kennedy, B. Peters, G. Q. Lu and
S. Z. Qiao, Nanoscale, 2012, 4, 970–975.
33 P. H. C. Camargo, L. Au, M. Rycenga, W. Li and Y. Xia,
Chem. Phys. Lett., 2010, 484, 304–308.
34 X. Du, L. Xiong, S. Dai and S. Z. Qiao, Adv. Healthcare
Mater., 2015, 4, 771–781.
Nanoscale Paper
This journal is © The Royal Society of Chemistry 2016 Nanoscale, 2016, 8, 12803–12811 | 12811
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 3
0 
M
ay
 2
01
6.
 D
ow
nl
oa
de
d 
on
 0
7/
06
/2
01
7 
05
:3
0:
52
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
